A clinical review article highlights Retatrutide as a breakthrough triple agonist targeting GLP-1, GIP, and glucagon receptors. It notes that this mechanism may offer superior weight reduction and metabolic improvement compared to Semaglutide and Tirzepatide by enhancing energy expenditure alongside appetite suppression.